acquisitions, Biotech, Diagnostics
PerkinElmer-ViaCell Deal Clears Antitrust Hurdle
Rebecca Zacks 10/25/07
Yesterday marked the expiration of the antitrust waiting period for Waltham, MA-based PerkinElmer’s (NYSE: PKI) planned acquisition of Cambridge’s ViaCell (NASDAQ: VIAC). The $300 million deal, announced about three weeks ago, boosted ViaCell’s shares more than 50 percent, and should close later this quarter.
Share
